BVF Inc’s Repare Therapeutics RPTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-10,333,600
Closed -$26.9M 45
2025
Q4
$26.9M Hold
10,333,600
0.9% 29
2025
Q3
$18.2M Hold
10,333,600
0.74% 29
2025
Q2
$14.4M Hold
10,333,600
0.51% 30
2025
Q1
$10.2M Hold
10,333,600
0.42% 33
2024
Q4
$13.5M Hold
10,333,600
0.46% 35
2024
Q3
$35.5M Hold
10,333,600
1.04% 28
2024
Q2
$34.1M Hold
10,333,600
0.96% 28
2024
Q1
$48.7M Hold
10,333,600
1.34% 22
2023
Q4
$75.4M Buy
10,333,600
+2,041,612
+25% +$11.4M 1.89% 13
2023
Q3
$100M Hold
8,291,988
2.7% 8
2023
Q2
$87.7M Hold
8,291,988
2.45% 11
2023
Q1
$81.6M Hold
8,291,988
2.98% 9
2022
Q4
$122M Hold
8,291,988
5.15% 3
2022
Q3
$101M Hold
8,291,988
4.15% 5
2022
Q2
$116M Buy
8,291,988
+2,433,212
+42% +$28.7M 5.6% 1
2022
Q1
$83.4M Buy
5,858,776
+1,000,015
+21% +$14.8M 3.34% 9
2021
Q4
$102M Buy
4,858,761
+1,136,363
+31% +$26.8M 3.72% 7
2021
Q3
$97.7M Hold
3,722,398
3.81% 7
2021
Q2
$116M Hold
3,722,398
4.35% 8
2021
Q1
$114M Buy
3,722,398
+750,207
+25% +$25.5M 4.28% 6
2020
Q4
$102M Sell
2,972,191
-92,543
-3% -$2.77M 4.01% 6
2020
Q3
$94.3M Buy
3,064,734
+1,120,188
+58% +$29.7M 5.14% 3
2020
Q2
$60.3M Buy
+1,944,546
New +$62.4M 3.72% 9

BVF Inc's RPTX Position: Q1 2026 in Review

BVF Inc sold out of Repare Therapeutics (RPTX) in Q1 2026, closing a stake of 10,333,600 shares — an estimated $26.9M sold.

BVF Inc first reported a position in RPTX in Q2 2020 and held it in 23 quarters. The position peaked at $122M in Q4 2022. 0 funds tracked by Wall St. Rank hold RPTX as of Q1 2026.

  • BVF Inc reported no remaining Repare Therapeutics position as of Q1 2026 after selling out during the quarter.
  • BVF Inc sold 10,333,600 Repare Therapeutics shares in Q1 2026, an estimated $26.9M.
  • BVF Inc first reported a position in Repare Therapeutics in Q2 2020 and held it in 23 quarters.
  • BVF Inc's Repare Therapeutics position peaked at $122M in Q4 2022.
  • 0 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2026.

Based on BVF Inc's 13F filing for Q1 2026, filed 15 May 2026.